Pvg Asset Management Corp Hepion Pharmaceuticals, Inc. Transaction History

Pvg Asset Management Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.27 - $11.9 $12,619 - $556,206	-46,740 Reduced 43.31%	61,175 $18,000
Q3 2022 Oct 13, 2022	BUY	$0.51 - $10.4 $3,991 - $81,390	7,826 Added 7.82%	107,915 $0
Q4 2021 Feb 02, 2022	BUY	$1.14 - $1.58 $54,833 - $75,998	48,100 Added 92.52%	100,089 $114,000
Q3 2021 Nov 10, 2021	SELL	$1.39 - $2.1 $191,301 - $289,016	-137,627 Reduced 72.58%	51,989 $79,000
Q2 2021 Aug 17, 2021	BUY	$1.56 - $2.26 $273,742 - $396,575	175,476 Added 1240.99%	189,616 $375,000
Q1 2021 May 14, 2021	BUY	$1.77 - $2.98 $25,027 - $42,137	14,140 New	14,140 $26,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $49.5M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Pvg Asset Management Corp with notifications on news.